Cross-sectional examination of metabolites and metabolic phenotypes in uremia

[1]  T. Zeller,et al.  Integrated genomics and metabolomics in nephrology. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  R. Sinha,et al.  Human metabolic correlates of body mass index , 2014, Metabolomics.

[3]  Connie M. Rhee,et al.  Updates on the Management of Diabetes in Dialysis Patients , 2014, Seminars in dialysis.

[4]  M. Patti,et al.  Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin. , 2014, The Journal of clinical endocrinology and metabolism.

[5]  R. Gerszten,et al.  A Plasma Long‐Chain Acylcarnitine Predicts Cardiovascular Mortality in Incident Dialysis Patients , 2013, Journal of the American Heart Association.

[6]  W. van Biesen,et al.  Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall. , 2013, Journal of the American Society of Nephrology : JASN.

[7]  Christian Gieger,et al.  Biomarkers for Type 2 Diabetes and Impaired Fasting Glucose Using a Nontargeted Metabolomics Approach , 2013, Diabetes.

[8]  J. Clemente,et al.  Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice , 2013, Science.

[9]  R. Vasan,et al.  A combined epidemiologic and metabolomic approach improves CKD prediction. , 2013, Journal of the American Society of Nephrology : JASN.

[10]  W. Strodel,et al.  A Role for Fibroblast Growth Factor 19 and Bile Acids in Diabetes Remission After Roux-en-Y Gastric Bypass , 2013, Diabetes Care.

[11]  D. Munn,et al.  Indoleamine 2,3 dioxygenase and metabolic control of immune responses. , 2013, Trends in immunology.

[12]  V. Mootha,et al.  Circulating branched‐chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents , 2013, Pediatric obesity.

[13]  A. Peters,et al.  Identification of Serum Metabolites Associated With Risk of Type 2 Diabetes Using a Targeted Metabolomic Approach , 2013, Diabetes.

[14]  Christian Gieger,et al.  Novel biomarkers for pre-diabetes identified by metabolomics , 2012, Molecular systems biology.

[15]  Raymond Vanholder,et al.  Normal and pathologic concentrations of uremic toxins. , 2012, Journal of the American Society of Nephrology : JASN.

[16]  Susan Cheng,et al.  Metabolite Profiling Identifies Pathways Associated With Metabolic Risk in Humans , 2012, Circulation.

[17]  David S. Wishart,et al.  MetaboAnalyst 2.0—a comprehensive server for metabolomic data analysis , 2012, Nucleic Acids Res..

[18]  V. Mootha,et al.  Metabolite profiles and the risk of developing diabetes , 2011, Nature Medicine.

[19]  M. Kohno,et al.  Metabolomic analysis of human plasma from haemodialysis patients , 2011, European journal of clinical investigation.

[20]  R. Gerszten,et al.  Metabolite profiling identifies markers of uremia. , 2010, Journal of the American Society of Nephrology : JASN.

[21]  J. Stasch,et al.  Kynurenine is an endothelium-derived relaxing factor produced during inflammation , 2010, Nature Medicine.

[22]  Arvind Ramanathan,et al.  A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells , 2010, Proceedings of the National Academy of Sciences.

[23]  C. Wanner,et al.  PROGRESS IN UREMIC TOXIN RESEARCH: The Role of EUTox in Uremic Toxin Research , 2009, Seminars in dialysis.

[24]  R. Vanholder,et al.  PROGRESS IN UREMIC TOXIN RESEARCH: Protein‐Bound Toxins—Update 2009 , 2009, Seminars in dialysis.

[25]  David S. Wishart,et al.  MetaboAnalyst: a web server for metabolomic data analysis and interpretation , 2009, Nucleic Acids Res..

[26]  Svati H Shah,et al.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. , 2009, Cell metabolism.

[27]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[28]  J. Klein,et al.  Risk factors for non-fatal myocardial infarction and cardiac death in incident dialysis patients. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  J. Jankowski,et al.  A bench to bedside view of uremic toxins. , 2008, Journal of the American Society of Nephrology : JASN.

[30]  K. Kalantar-Zadeh,et al.  CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Introduction: The Reverse Epidemiology Controversy , 2007, Seminars in dialysis.

[31]  J. Kopple.  CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: How to Reconcile Conventional and Altered Risk Factor Patterns in Dialysis Patients , 2007, Seminars in dialysis.

[32]  X. Leverve,et al.  Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. , 2007, Journal of the American Society of Nephrology : JASN.

[33]  Brenda W Gillespie,et al.  Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[34]  Marcello Tonelli,et al.  Cohort studies: marching forward. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[35]  S. Greenland,et al.  Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  S. Greenland,et al.  Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[38]  S. Greenland,et al.  Reverse Epidemiology of Hypertension and Cardiovascular Death in the Hemodialysis Population: The 58th Annual Fall Conference and Scientific Sessions , 2005, Hypertension.

[39]  M. Hernán,et al.  Activated injectable vitamin D and hemodialysis survival: a historical cohort study. , 2005, Journal of the American Society of Nephrology : JASN.

[40]  M. Wolf,et al.  Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. , 2003, The New England journal of medicine.

[41]  Raymond Vanholder,et al.  Review on uremic toxins: classification, concentration, and interindividual variability. , 2003, Kidney international.

[42]  K. Kalantar-Zadeh,et al.  Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. , 2003, Kidney international.

[43]  M. Vettore,et al.  Phenylalanine hydroxylation across the kidney in humans rapid communication. , 1999, Kidney international.

[44]  E. Lowrie,et al.  Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. , 1999, Kidney international.

[45]  R. Wolfe,et al.  Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[46]  K. Iseki,et al.  Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. , 1997, Kidney international.

[47]  C. Scrimgeour,et al.  Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation. , 1993, The American journal of physiology.

[48]  E G Lowrie,et al.  Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[49]  K. Kalantar-Zadeh,et al.  Why is protein-energy wasting associated with mortality in chronic kidney disease? , 2009, Seminars in nephrology.

[50]  J. Kopple,et al.  Causes and prevention of protein-energy wasting in chronic kidney failure. , 2009, Seminars in nephrology.

[51]  S. Mundra,et al.  Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis , 2009 .

[52]  K. Kalantar-Zadeh,et al.  Introduction: the reverse epidemiology controversy. , 2007, Seminars in dialysis.

[53]  K. Kalantar-Zadeh,et al.  Association between serum lipids and survival in hemodialysis patients and impact of race. , 2007, Journal of the American Society of Nephrology : JASN.

[54]  S. Greenland,et al.  Kalantar-Zadeh, K. et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol. Dial. Transplant. 20, 1880-1888 , 2005 .